Rigel has a global exclusive license agreement with Eli Lilly for Rigel’s RIPK1 inhibitor programs in all indications.
This collaboration includes the development and commercialization of ocadusertib (previously LY3871801/R552), a potent and selective receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases.
Enrollment in Lilly's Phase 2a clinical trial (NCT05848258) studying ocadusertib in adult patients with moderately to severely active rheumatoid arthritis is ongoing. Pursuant to the collaboration, Lilly also leads all preclinical and clinical development of brain penetrating RIPK1 inhibitors in central nervous system (CNS) diseases.
Rigel received an upfront payment, and is eligible for development, regulatory, and commercial milestone payments, and tiered royalty payments on any future net sales of any products emerging from the collaboration.
In early October, Rigel received notification from Lilly that it will terminate the CNS disease program, which will become effective 60 days following notification.